News & Events

Biome Diagnostics again under Top 100 Start-Ups in Austria!

By January 25, 2022No Comments

VIENNA, November 2021: Biome Diagnostics, previously known as myBioma, has been mentioned as number 51 in the Top 100 best Start-Ups in Austria according to the Ranking from the magazine Trend! (https://www.trend.at/trendventure/oesterreichs-beste-start-ups)

Every year the magazine Trend nominates the Top 100 Start-Ups in Austria. Biome Diagnostics is for second time listed! This is motivating for the entire team and inspires to keep innovating and producing new cutting-edge microbiome-based technologies!

About BiomeOne®

BiomeOne describes the current efforts of BiomeDx towards the world’s first stool-based response prediction test for immunotherapy (ICI). Currently, the biomarker is tested in three tumor types: non-small-cell lung cancer, renal cell carcinoma and malignant melanoma. Early research efforts support the idea of a tumor agnostic biomarker that can be used for any tumor type. Read more on BiomeOne.

About BiomeDx®

Biome Diagnostics GmbH (BiomeDx) is world leader in microbiome diagnostic products for oncology. The Austrian based MedTech company is committed to advance precision medicine by pioneering microbiome-based technologies that transform cancer care. The company is strategically positioned at the intersection of state-of-the-art DNA sequencing and advanced machine learning algorithms to develop first in class technologies for routine clinical practice. It is the world first microbiome company certified according to ISO 13485:2016 and ISO 9001:2015.